Full Press Release Details
Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,
make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising
from or in reliance upon the whole or any part of the contents of this announcement.
ASCENTAGE PHARMA GROUP INTERNATIONAL
(Incorporated in the Cayman Islands
with limited liability)
VOLUNTARY ANNOUNCEMENT
PURCHASE OF SHARES BY THE TRUSTEE
FOR THE PURPOSE OF THE 2022 RSU SCHEME
This announcement is made by Ascentage
Pharma Group International (the "Company") on a voluntary basis. Reference is made to the announcements of the Company
dated June 23, 2022, July 14, 2022, October 21, 2022, October 25, 2022, October 26, 2022, October 27, 2022, October 28, 2022, October
31, 2022, May 8, 2023, November 13, 2023, November 14, 2023, November 16, 2023, February 2, 2024, September 2, 2024, October 25, 2024,
March 31, 2025, April 8, 2025, April 30, 2025, June 27, 2025, November 27, 2025, December 30, 2025, April 20, 2026, April 30, 2026, May
27, 2026, May 28, 2026 and June 10, 2026 (the "Announcements") in relation to, among other things, (i) the adoption
of and amendments to the 2022 RSU Scheme; (ii) the initial grant and the further grants of the 2022 Awards thereunder; and (iii) the purchase
of existing Shares by the Trustee on-market for the purpose of the 2022 RSU Scheme. Unless otherwise defined, capitalized terms used herein
shall have the same meanings as those defined in the Announcements.
On June 11, 2026, the Trustee purchased
a total of 110,000 existing Shares (the "Purchased Shares") on-market for the purpose of the 2022 RSU Scheme to satisfy
the RSUs upon vesting. Details of the Purchased Shares and the latest information about the Shares held by the Trustee under the Scheme
| Purchase date | : | June 11, 2026 |
| Total number of the Purchased Shares | : | 110,000 Shares |
| Percentage of the Purchased Shares to the total number of issued Shares as at the date of this announcement | : | Approximately 0.0294% |
| Total consideration paid for the Purchased Shares (excluding all related expenses, transaction levy, brokerage, tax, duties and levies) | : | HK$3,671,094 |
| Average consideration per Purchased Share (excluding all related expenses, transaction levy, brokerage, tax, duties and levies) | : | Approximately HK$33.37 |
| Total number of existing Shares purchased by the Trustee on-market for the purpose of the 2022 RSU Scheme immediately after the aforesaid purchases | : | 2,615,000 Shares |
The Purchased Shares are currently
held by the Trustee in accordance with the 2022 RSU Scheme Rules and the terms of the trust deed entered into between the Company and
the Trustee. The Trustee shall not exercise the voting rights attached to the Shares held on trust by it. As at the date of this announcement,
no further grant of Awards has been made pursuant to the 2022 RSU Scheme apart from the initial grant of the 2022 Awards on June 23, 2022
and the further grants of the 2022 Awards on May 4, 2023, September 2, 2024, June 27, 2025, November 26, 2025 and April 20, 2026 as disclosed
in the Announcements.
| By Order of the Board | |
| Ascentage Pharma Group International Dr. Yang Dajun | |
| Chairman and Executive Director |
Suzhou, People's Republic of China, June 11, 2026
As at the date of this announcement, the
Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon DazhongNote
1 as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky Note
2, Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.
| 1. | Dr. Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements. |
| 2. | Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company. |